Mylan plant
Home A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z

Mylan plant



Mylan

9.21.2017 | Nicholas Babcock
Mylan plant
Mylan

Mylan N.V. is an American global generic and specialty pharmaceuticals company registered in.. In 2015 three plants acquired in that deal were issued warning letters by the FDA. After successful lobbying from Mylan, in 2013, the "School.

UDL Laboratories (Acq 1996).

In 2015 three plants acquired in that deal were issued warning letters by the FDA. In 2013 Mylan acquired an Indian generic injectable drugs company, Agila Specialties Private, for $1.6 billion in cash.

In 1987 Mylan agreed to enter into a joint venture with Bolar to buy Somerset Pharmaceuticals; Mylan wanted access to Somersets' drug discovery capabilities as well as its new drug for Parkinson's, selegiline ; the deal was completed in 1988 but its consummation was dependent on FDA approval of selegiline, which came in 1989.

In July, Teva dropped its bid for Mylan and instead acquired Allergan 's generic drug business for about the same price.

About Us Mylan

12.24.2017 | Ashley Kendal
Mylan plant
About Us Mylan

Our approximay 50 plants around the world manufacture tens of billions of doses of medicine annually, and each site adheres to stringent quality standards.

Our acquisition of Bioniche Pharma expands our injectable portfolio with products for use in orthopaedics, rheumatology, urology and dermatology.

We become a global company by acquiring a controlling interest in Matrix Laboratories and by purchasing Merck KGaA’s generics business.

We become the most-dispensed line of brand and generic pharmaceuticals in the U.S.

Our most valuable asset is our global workforce, each member of which is a passionate supporter of our cause to deliver better health for a better world.

Please select one of our websites from the list below.

We are ready, having put in place a plan to expand through organic growth and acquisitions from a mid-size company into a global leader.

FDA jumps on another Mylan plant in India, slapping it with a

3.15.2017 | John Addington
Mylan plant
FDA jumps on another Mylan plant in India, slapping it with a

The FDA has issued a warning letter to another Mylan plant in India for ongoing data integrity issues. In the letter, the agency said investigators.

It pointed out that the warning letter for the U.S. The FDA this year issued a warning letter to a Wockhardt plant in India for issues including data integrity. It followed that up with a warning for a Wockhardt plant in the U.S. plant was the company’s sixth for seven Wockhardt plants, three of which have been banned from shipping to the U.S. that castigated the company for not getting on top of these issues despite ongoing FDA discussions about its problems at other Mylan plants. Problems with data integrity have plagued many Indian drugmakers, like Sun Pharma and Wockhardt, resulting in an avalanche of FDA warning letters in the last few years.

It noted that even though the facility invalidated 101 of 139 initial out-of-specification (OOS) assay results, about 72%, employees never thoroughly investigated to find the root cause of the issues and didn’t include them in the results reported to the agency.

Less than two years after being slapped hard by the FDA for problems at three plants it got in its buyout of a sterile injectables specialist Agila Specialties, another Mylan plant in India has been issued a warning letter for ongoing data integrity issues.

The lab blamed the problems on power interruptions and computer connectivity problems, but couldn’t explain why they so often happened in the lab and why it didn’t bother to find a root cause.

Mylan Gets FDA Warning on Drug Quality at Factory in India

7.19.2017 | Kaitlyn Leapman
Mylan plant
Mylan Gets FDA Warning on Drug Quality at Factory in India

Drugmaker Mylan NV failed to investigate why medications made at a factory in India didn't meet quality standards and frequently didn't report.

The company didn’t investigate the reason for those failures, nor did it probe error signals that indicate lost or deleted quality data, the agency said. Mylan invalidated 101 out of 139 tests that showed from January through June 2016 that drug batches didn’t meet certain quality specifications, according to the FDA, which inspected the plant in September.

EMEA +44 20 7330 7500.

The shares fell as much as 2.2 percent. The quality system at Mylan’s facility in Maharashtra, India, “does not adequay ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture,” the Food and Drug Administration told the company in a warning letter  dated April 3 that was posted Tuesday.

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accuray delivers business and financial information, news and insight around the world.

The stock was down 1.9 percent to $38.50 at 12:12 p.m.

FDA warns Mylan over quality concerns at India facility

6.18.2017 | Ashley Kendal
Mylan plant
FDA warns Mylan over quality concerns at India facility

The FDA has raised concerns over quality controls at a Mylan manufacturing plant in India.

India-based drug manufacturing facilities have been criticized by the FDA in recent years for violating quality standards, as the agency increases oversight of key suppliers to the United States.

More "Boardroom 2030" »

The FDA had in 2015 had sent a warning letter expressing concerns over quality controls at three Mylan facilities in the south Indian city of Bengaluru.

Follow Reuters on Twitter. 2017. Read the original article on Reuters.

The CEO of Mondelēz doesn’t seem interested in buying Nestlé’s candy business.

More "The Bottom Line" »

Available on iOS or Android.

Until the regulator can confirm Mylan's compliance with standard manufacturing practices, it may withhold approval of any new applications listing the firm as a drug manufacturer, the FDA said.

The agency's concerns stem from an inspection in September of a facility located at Nashik in the western Indian state of Maharashtra that produces antiretroviral therapies (ARVs) used to treat HIV.

Mylan's shares were down 1.9 percent at $38.50 in afternoon trading on the Nasdaq.

(Reuters) - The U.S.